Mounjaro maker pauses shipments of weight-loss drug to UK | Prescription drugs business

The producer of the load loss drug Mounjaro has paused shipments to the UK earlier than a major value rise for the therapy subsequent month.

The US pharmaceutical firm Eli Lilly is because of enhance the UK record value of the drug by as much as 170% from September, amid a White Home push to get drugmakers to lift drugs costs in Europe to permit for value cuts within the US.

The corporate mentioned that with the intention to handle its provide and make sure that sufferers maintained entry, it had allocations in place for pharmacies and suppliers that ordered medicines from the corporate.

There have been authorized protections to forestall inappropriate stockpiling of medicines by suppliers, Eli Lilly mentioned. It plans to renew orders on 1 September.

The rise in costs may end in a month’s provide of the best dose of the medication growing from £122 to £330 ($165 to $445).

Eli Lilly has reportedly advised its two British wholesalers to quickly cease taking orders after demand soared earlier than the value enhance comes into power on 1 September. Pharmacies mentioned there had been panic shopping for of the drug because the value announcement this month.

Individuals utilizing Mounjaro have been warned towards switching to sellers on the hidden financial system or bulk shopping for.

Whereas many pay for the drug within the UK, it turned accessible on the NHS on the finish of June, and Eli Lilly says the upper value won’t have an effect on those that get it by means of the well being service.

Mounjaro – additionally recognized by its generic title tirzepatide – has develop into a well-liked different to probably the most well-known weight reduction drug, Ozempic. Each medicine, that are taken as weekly injections, have been developed as remedies for sort 2 diabetes.

When it was launched in Britain in February 2024, Eli Lilly agreed to a listing value “considerably beneath” its different European markets to cease delays in availability of the medication by means of the NHS.

The rise within the record value will align it extra persistently, the corporate has mentioned, though it added that the NHS wouldn’t pay the brand new, increased value to make sure continued entry for individuals with weight problems and sort 2 diabetes receiving it by means of the well being service.

On 31 July, Donald Trump despatched letters to 17 of the world’s largest drugmakers, together with Eli Lilly and Novo Nordisk, demanding cuts to costs for Individuals inside 60 days.

In Might, the US president advised reporters {that a} good friend in London had advised him he had purchased the “fat-shot drug” for $88, in contrast with $1,300 in New York.